Animals bearing a cachexia-inducing tumour, the MAC16 adenocarcinoma, showed a progressive decrease in blood glucose levels with increasing weight loss, while animals bearing a histologically similar tumour, the MAC13 adenocarcinoma, showed no change in either body weight or blood glucose levels with growth of the tumour. The effect of the MAC16 tumour on blood glucose levels appeared to be unrelated to food intake, glucose consumption by the tumour, or to the production of increased levels of IGF-I and IGF-II mRNA by the tumour cells. The relationship between the induction of cachexia and alteration in blood glucose levels remains unknown.
Tumour-associated hypoglycaemia in a murine cachexia model 
Summary
Animals bearing a cachexia-inducing tumour, the MAC16 adenocarcinoma, showed a progressive decrease in blood glucose levels with increasing weight loss, while animals bearing a histologically similar tumour, the MAC13 adenocarcinoma, showed no change in either body weight or blood glucose levels with growth of the tumour. The effect of the MAC16 tumour on blood glucose levels appeared to be unrelated to food intake, glucose consumption by the tumour, or to the production of increased levels of IGF-I and IGF-II mRNA by the tumour cells. The relationship between the induction of cachexia and alteration in blood glucose levels remains unknown.
A high rate of glucose consumption under both anaerobic and aerobic conditions is a characteristic feature of both experimental (Weber et al., 1961; Weber, 1977) and human tumours (Nolop et al., 1987) . Alterations in glucose metabolism in tumour cells are associated with an increased intracellular concentration of glucose, which is tightly coupled with an over-expression of facilitative glucose transporter genes (Yamamoto et al., 1990) , an increased transcription of the hexokinase gene (Johansson et al., 1985) , as well as alterations in isoenzyme profiles of the enzymes involved in glycolysis (Weber et al., 1961) . The enhanced glucose transport is not insulin-dependent, since hypoglycaemia often develops in both tumour-bearing animals (Bibby et al., 1987) and cancer patients (Heber et al., 1985) with normal or even decreased blood insulin levels. The architecture of solid tumours also plays an important role in determining the metabolic substrate for energy production. Large solid tumours tend to have a poor blood supply, and consequently become hypoxic, in which case glucose will become the predominant metabolic substrate, since the Embden-Meyerhof pathway is the only means of ATP production in the absence of oxygen.
We have recently reported studies on glucose utilisation by tumour and host tissues in NMRI mice bearing the MAC16 colon adenocarcinoma, which is capable of inducing cachexia in recipient animals (Mulligan & Tisdale, 1991) . Glucose consumption by the tumour was second only to brain and the increased demand for glucose was met by a decrease in glucose utilisation by host organs and in particular the brain. This study further investigates changes in blood glucose levels and the possible role of insulin-like growth factors (IGF) in the MAC16 model. Since antibodies to both mouse IGFI and IGFII were not readily available, we have chosen to measure their production in the MAC16 tumour indirectly, through the study of gene expression.
Materials and methods
Pure strain NMRI mice were bred in our own colony and were fed on a rat and mouse breeding diet (Pilsbury, Birmingham, UK) and water ad libitum. Fragments (1 x 2 mm) of either the MAC16 or MAC13 tumour were implanted into the flank of male NMRI mice (starting weight 28 g) by means of a trocar as described (Bibby et al., 1987 declined in proportion to weight loss ( Figure 1 ) with a minimum value when weight loss was approximately 20% and the tumour volume was 680 mm3. In contrast, animals bearing the MAC13 tumour, which did not induce weight loss, showed no decrease in blood glucose levels during the course of the experiment (Figure 2) . In order to reduce the fluctuation in food and water intake due to the stress induced by blood sampling, a separate experiment was performed where blood glucose was only measured at the start (123 ± 3.2 mg 100 ml1') and end (100 ± 3.6 mg 100 ml1') of the experiment. In this case food and water intake remained at control levels with little fluctuation, even after the onset of weight loss (Figure 3) . In some cases food intake dropped when the weight loss approached 30%. In order to try to determine the mechanism responsible for the decrease in blood glucose in animals bearing the MAC16 tumour, the expression of the genes for IGFI and IGFII were assessed in both the MAC16 and MAC13 tumour types. Poly(A)+RNA was purified from total RNA through oligo dT-cellulose columns and the yield was approximately 1.3%. Formaldehyde gel electrophoresis showed that the RNA was intact. Using RNA from the liver of newborn rats as a positive control for expression of IGFII, a strong signal was obtained using a rat oligonucleotide probe (Figure 4 either cell line using a mouse or human IGFI cDNA probe. Poly(A)+RNA was also extracted from MAC16 tumours removed from eight mice, all of which were hypoglycaemic. Total RNA extracted appeared intact, as shown by formaldehyde gel electrophoresis. Again no transcripts for IGFII were detected in any of the samples of poly(A)+RNA from the cachectic, hypoglycaemic mice ( Figure 5 ). Thus it was concluded that the genes for IGFI and IGFII were not expressed by the MAC 16 or MAC1 3 cells either in vitro or in vivo.
Discussion
Tumour associated hypoglycaemia is often seen in cancer patients with large mesenchymal tumours (Kahn, 1980) and it has been suggested that since hypoglycaemia usually occurs when the tumour has reached a large size, the high glycolytic activity of the tumour tissue might lead to a depjletion of circulating glucose. However, in the case of the MAC16 adenocarcinoma, hypoglycaemia occurs when the tumour mass is small, suggesting the production by the tumour of peptides that mimic the effect of insulin. The most obvious candidates are the insulin-like growth factors, Which are single chain polypeptides evolutionary related to insulin. Elevated levels of IGF mRNA have been found in a number of tumour types of mesenchymal origin, associated with hypoglycaemia (Tricoli et al., 1986; Hoppener et al., 1988; Schofield et al., 1989) . Animals bearing the MAC16 adenocarcinoma show a progressive decrease in blood glucose levels as weight loss increases. The decrease in blood glucose level appears to be a 1 2 3 4 5 6 1 2 3 4 5 specific to the cachectic state, since animals bearing a closely related tumour, the MAC13 adenocarcinoma, which does not produce weight loss, show normal levels of blood glucose despite progressive tumour growth. Low blood glucose levels would be expected to trigger glucose-generating pathways such as gluconeogenesis from sources such as lactate, alanine and glycerol. The plasma levels of both lactate (Bibby et al., 1987) and alanine (Beck & Tisdale, 1989) have been found to be decreased in animals bearing the MAC16 tumour, while urinary nitrogen levels have been found to be increased. This increased use of amino acids for gluconeogenesis would lead to catabolism of muscle proteins as observed with this tumour model (Beck & Tisdale, 1987) . The difference in ability to maintain blood glucose levels in animals bearing the MAC16 and MAC13 tumours appears to be unrelated either to food intake or the glucose consumption by the tumour cells, since glucose utilisation by the MAC13 tumour has been shown to be significantly higher than by the MAC16 tumour (Mulligan & Tisdale, 1991) . McFadzean and Yeung (1969) were able to separate two types of hypoglycaemia in patients with hepatocellular carcinoma. Those with type A hypoglycaemia developed mild reductions in plasma glucose associated with cachexia, while those with type B hypoglycaemia demonstrated marked decreases in glucose levels in patients in whom cachexia was not a feature. The decreases in blood glucose in the latter group of patients appear to arise from an increased IGFII high molecular weight production by the tumour cells (Shapiro et al., 1990) . In the present study we have been unable to demonstrate increased levels of IGFI or IGFII mRNA in the MAC 16 tumour either in vitro or in vivo although failure to detect increased gene transcription does (Shapiro et al., 1990) , which are associated with a profound disturbance of the serum IGF binding protein levels. Previous studies have also shown a decreased plasma insulin level, which may be a response to the falling blood glucose (Bibby et al., 1987) . Thus the mechanism for the decrease in blood glucose accompanying weight loss in the MAC 16 tumour model remains unknown. A possible candidate is a substance immunochemically cross-reactive with insulin (SICRI), which has been shown to be produced by murine B16 melanoma cells in vivo (Vuk-Pavlovic et al., 1986) . Increased levels of SICRI were correlated with decreased blood glucose concentrations by stimulating glucose uptake by adipose tissue. The coincidence of a negative nitrogen balance with hypoglycaemia is not consistent with the simple overproduction of IGFs and the data supports this hypothesis. The results presented here indicate the need for a new candidate molecule for the causation of the hypoglycaemic/cachectic state as mimicked in this model system.
